样式: 排序: IF: - GO 导出 标记为已读
-
A glimpse into cofilin-1 role in cancer therapy: A potential target to improve clinical outcomes? Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-02-22 Annie Cristhine Moraes Sousa-Squiavinato, Jose Andrés Morgado-Díaz
Cofilin-1 (CFL1) modulates dynamic actin networks by severing and enhancing depolymerization. The upregulation of cofilin-1 expression in several cancer types is associated with tumor progression and metastasis. However, recent discoveries indicated relevant cofilin-1 functions under oxidative stress conditions, interplaying with mitochondrial dynamics, and apoptosis networks. In this scenario, these
-
Small extracellular vesicles from surviving cancer cells as multiparametric monitoring tools of measurable residual disease and therapeutic efficiency Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-02-20 Gábor Valcz, Edit I. Buzás, Robert A. Gatenby, Beáta Újvári, Béla Molnár
-
Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-02-12 Xinyang Li, Meng Wu, Jie Lu, Jinming Yu, Dawei Chen
Immunotherapy has revolutionized cancer treatment. However, it's well-recognized that a considerable proportion of patients fail to benefit from immunotherapy, and to improve immunotherapy response is clinically urgent. Insufficient immune infiltration and immunosuppressive tumor microenvironments (TME) are main contributors to immunotherapy resistance. Thus sustaining functional self-renewal capacity
-
Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-02-09 Yuan-dong Sun, Hao Zhang, Yuan-min Li, Jian-jun Han
Metabolic associated fatty liver disease (MAFLD) is a significant risk factor for the development of hepatocellular carcinoma (HCC). Hepatic stellate cells (HSCs), as key mediators in liver injury response, are believed to play a crucial role in the repair process of liver injury. However, in MAFLD patients, the normal metabolic and immunoregulatory mechanisms of HSCs become disrupted, leading to disturbances
-
PBX1 as a novel master regulator in cancer: Its regulation, molecular biology, and therapeutic applications Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-02-08 Ting-Wan Kao, Hsiao-Han Chen, James Lin, Tian-Li Wang, Yao-An Shen
PBX1 is a critical transcription factor at the top of various cell fate-determining pathways. In cancer, PBX1 stands at the crossroads of multiple oncogenic signaling pathways and mediates responses by recruiting a broad repertoire of downstream targets. Research thus far has corroborated the involvement of PBX1 in cancer proliferation, resisting apoptosis, tumor-associated neoangiogenesis, epithelial-mesenchymal
-
Mechanistic regulation of FOXO transcription factors in the nucleus Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-02-02 Xiaowei Guo, Kai Peng, Yanwen He, Lei Xue
FOXO proteins represent evolutionarily conserved transcription factors (TFs) that play critical roles in responding to various physiological signals or pathological stimuli, either through transcription-dependent or -independent mechanisms. Dysfunction of these proteins have been implicated in numerous diseases, including cancer. Although the regulation of FOXO TFs shuttling between the cytoplasm and
-
Expression and function of NF-Y subunits in cancer Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-02-02 Diletta Dolfini, Nerina Gnesutta, Roberto Mantovani
NF-Y is a Transcription Factor (TF) targeting the CCAAT box regulatory element. It consists of the NF-YB/NF-YC heterodimer, each containing an Histone Fold Domain (HFD), and the sequence-specific subunit NF-YA. NF-YA expression is associated with cell proliferation and absent in some post-mitotic cells. The review summarizes recent findings impacting on cancer development. The logic of the NF-Y regulome
-
VEGF signaling: Role in angiogenesis and beyond Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-01-26 Pallab Shaw, Shailendra Kumar Dhar Dwivedi, Resham Bhattacharya, Priyabrata Mukherjee, Geeta Rao
Angiogenesis is a crucial process for tissue development, repair, and tumor survival. Vascular endothelial growth factor (VEGF) is a key driver secreted by cancer cells, promoting neovascularization. While VEGF's role in angiogenesis is well-documented, its influence on the other aspects in tumor microenvironemt is less discussed. This review elaborates on VEGF's impact on intercellular interactions
-
Review of pre-metastatic niches in lung metastasis: From cells to molecules, from mechanism to clinics Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-01-26 Hongting Xie, Quan Sun, Xuelei Chu, Shijie Zhu, Feiyu Xie
Distant metastasis is responsible for high mortality in most cancer cases and the lung is one of the most common target organs, severely affecting the quality of daily life and overall survival of cancer patients. With relevant research breakthroughs accumulating, scientists have developed a deeper understanding of lung metastasis (LM) from the rudimentary “seed and soil” theory to a more vivid concept
-
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-01-24 Rolf I. Skotheim, Mari Bogaard, Kristina T. Carm, Ulrika Axcrona, Karol Axcrona
Prostate cancer is unique compared to other major cancers due to the presence of multiple primary malignant foci in the majority of patients at the time of diagnosis. Each malignant focus has distinct somatic mutations and gene expression patterns, which represents a challenge for the development of prognostic tests for localized prostate cancer. Additionally, the molecular heterogeneity of advanced
-
-
Breaking the stromal barrier in pancreatic cancer: Advances and challenges Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-30 Mohana Chakkera, Jeremy B. Foote, Batoul Farran, Ganji Purnachandra Nagaraju
-
Targeting the heat shock response induced by modulated electro-hyperthermia (mEHT) in cancer Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-01-02 Pedro Viana, Péter Hamar
The Heat Shock Response (HSR) is a cellular stress reaction crucial for cell survival against stressors, including heat, in both healthy and cancer cells. Modulated electro-hyperthermia (mEHT) is an emerging non-invasive cancer therapy utilizing electromagnetic fields to selectively target cancer cells via temperature-dependent and independent mechanisms. However, mEHT triggers HSR in treated cells
-
Advances and prospects of mRNA vaccines in cancer immunotherapy Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2024-01-01 Yixuan Liu, Qijia Yan, Zhaoyang Zeng, Chunmei Fan, Wei Xiong
Cancer vaccines, designed to activate the body's own immune system to fight against tumors, are a current trend in cancer treatment and receiving increasing attention. Cancer vaccines mainly include oncolytic virus vaccine, cell vaccine, peptide vaccine and nucleic acid vaccine. Over the course of decades of research, oncolytic virus vaccine T-VEC, cellular vaccine sipuleucel-T, various peptide vaccines
-
Strategies for studying immune and non-immune human and canine mammary gland cancer tumour infiltrate Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-27 Oscar Hernán Rodríguez-Bejarano, Leonardo Roa, Giovanni Vargas-Hernández, Lucía Botero-Espinosa, Carlos Parra-López, Manuel Alfonso Patarroyo
The tumour microenvironment (TME) is usually defined as a cell environment associated with tumours or cancerous stem cells where conditions are established affecting tumour development and progression through malignant cell interaction with non-malignant cells. The TME is made up of endothelial, immune and non-immune cells, extracellular matrix (ECM) components and signalling molecules acting specifically
-
Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-30 Chenlin Ye, Nan Jiang, Jing Zheng, Shumeng Zhang, Jingchen Zhang, Jianya Zhou
Decitabine's early successful therapeutic outcomes in hematologic malignancies have led to regulatory approvals from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for addressing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These approvals have sparked keen interest in exploring the potential of decitabine for treating solid tumors. Continuous preclinical
-
Deregulated miRNAs in enzalutamide resistant prostate cancer: A comprehensive review of key molecular alterations and clinical outcomes Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-30 Inês Tavares, Mariana Morais, Francisca Dias, Rui Medeiros, Ana Luísa Teixeira
Prostate cancer (PC) is the second most frequently diagnosed cancer and the fifth leading cause of cancer-related deaths in male population worldwide. Since the growth and progression of PC highly depend on the androgen pathway, androgen deprivation therapy (ADT) is the mainstay of systemic treatment. Enzalutamide is a second-generation antiandrogen, which is widely used for the treatment of advanced
-
Nutrition and dietary restrictions in cancer prevention Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-24 Amrendra Mishra, Giacomo Giuliani, Valter D. Longo
The composition and pattern of dietary intake have emerged as key factors influencing aging, regeneration, and consequently, healthspan and lifespan. Cancer is one of the major diseases more tightly linked with aging, and age-related mortality. Although the role of nutrition in cancer incidence is generally well established, we are far from a consensus on how diet influences tumour development in different
-
Vitamin K: New insights related to senescence and cancer metastasis Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-28 Anqi Chen, Jialu Li, Nianxuan Shen, Haifeng Huang, Qinglei Hang
Several clinical trials and experimental studies have recently shown that vitamin K (VK) supplementation benefits the human body. Specifically, VK participates in coagulation and is associated with cellular senescence and cancer. VK has a potential anticancer effect in various cancers, such as pancreatic and prostate cancers. Through anti-inflammatory and antioxidant effects, VK can prevent senescence
-
Dietary approaches for exploiting metabolic vulnerabilities in cancer Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-28 Otília Menyhárt, Balázs Győrffy
-
Drivers of cancer metastasis – Arise early and remain present Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-25 Dagmara Dymerska, Anna A. Marusiak
Cancer and its metastases arise from mutations of genes, drivers that promote a tumor's growth. Analyses of driver events provide insights into cancer cell history and may lead to a better understanding of oncogenesis. We reviewed 27 metastatic research studies, including pan-cancer studies, individual cancer studies, and phylogenetic analyses, and summarized our current knowledge of metastatic drivers
-
Role of interferon regulatory factor 5 (IRF5) in tumor progression: Prognostic and therapeutic potential Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-21 Bailey K. Roberts, Gilbert Collado, Betsy J. Barnes
Canonically, the transcription factor interferon regulatory factor 5 (IRF5) is a key mediator of innate and adaptive immunity downstream of pathogen recognition receptors such as Toll-like receptors (TLRs). Hence, dysregulation of IRF5 function has been widely implicated in inflammatory and autoimmune diseases. Over the last few decades, dysregulation of IRF5 expression has been also reported in hematologic
-
Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-17 Aihong Wang, Yin Wang, Chenxiang Du, Huilun Yang, Zhengping Wang, Canhui Jin, Michael R. Hamblin
Ovarian cancer is a less common tumor in women compared to cervical or breast cancer, however it is more malignant and has worse outcomes. Ovarian cancer patients still have a five-year survival rate < 50% despite advances in therapy. Due to recent developments in immune checkpoint inhibitors (ICIs), cancer immunotherapy has attracted increased interest. Pyroptosis is a highly inflammatory form of
-
Cancer-associated thrombosis: What about microRNAs targeting the tissue factor coagulation pathway? Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-12 Valéria Tavares, Beatriz Vieira Neto, Inês Soares Marques, Joana Assis, Deolinda Pereira, Rui Medeiros
Cancer patients are often diagnosed with venous thromboembolism (VTE), a cardiovascular disease that substantially decreases their quality of life and survival rate. Haemostasis in these patients is deregulated, which is reflected in the common presentation of a blood hypercoagulation state. Despite the inconsistent results, existing evidence suggests that the expression of microRNAs (miRNAs) is deregulated
-
Long non-coding RNAs - SNHG6 emerge as potential marker in colorectal cancer Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-16 Michalina Jurkiewicz, Adrian Szczepaniak, Marta Zielińska
Colorectal cancer (CRC) ranks among the leading cancers in terms of incidence and mortality in the Western world. Currently, there are no sufficient diagnostic markers that would enable an early diagnosis and efficient therapy. Unfortunately, a significant number of new CRC cases is detected in late stages, with distant metastases, therefore, new therapeutic approaches, which would alleviate the prognosis
-
Glioblastoma preclinical models: Strengths and weaknesses Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-16 Vasavi Pasupuleti, Lalitkumar Vora, Renuka Prasad, D.N. Nandakumar, Dharmendra Kumar Khatri
Glioblastoma multiforme is a highly malignant brain tumor with significant intra- and intertumoral heterogeneity known for its aggressive nature and poor prognosis. The complex signaling cascade that regulates this heterogeneity makes targeted drug therapy ineffective. The development of an optimal preclinical model is crucial for the comprehension of molecular heterogeneity and enhancing therapeutic
-
Uveal melanoma modeling in mice and zebrafish Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-15 Quincy C.C. van den Bosch, Annelies de Klein, Robert M. Verdijk, Emine Kiliç, Erwin Brosens
Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic
-
Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastoma Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-14 Magdalena Kusaczuk, Elena Tovar Ambel, Monika Naumowicz, Guillermo Velasco
Despite the extensive efforts to find effective therapeutic strategies, glioblastoma (GBM) remains a therapeutic challenge with dismal prognosis of survival. Over the last decade the role of stress responses in GBM therapy has gained a great deal of attention, since depending on the duration and intensity of these cellular programs they can be cytoprotective or promote cancer cell death. As such, initiation
-
Targeting lipid metabolism in cancer metastasis Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-13 Gloria Pascual, Blanca Majem, Salvador Aznar-Benitah
This review delves into the most recent research on the metabolic adaptability of cancer cells and examines how their metabolic functions can impact their progression into metastatic forms. We emphasize the growing significance of lipid metabolism and dietary lipids within the tumor microenvironment, underscoring their influence on tumor progression. Additionally, we present an outline of the interplay
-
The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-12 Vanja Tadić, Wei Zhang, Anamaria Brozovic
High-grade serous ovarian cancer (HGSOC) is the most frequent and aggressive type of epithelial ovarian cancer, with high recurrence rate and chemoresistance being the main issues in its clinical management. HGSOC is specifically challenging due to the metastatic dissemination via spheroids in the ascitic fluid. The HGSOC spheroids represent the invasive and chemoresistant cellular fraction, which
-
TEAD4: A key regulator of tumor metastasis and chemoresistance - Mechanisms and therapeutic implications Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-08 Mohan Liu, Weina Hu, Xiaona Meng, Biao Wang
Cancer metastasis is a complex process influenced by various factors, including epithelial-mesenchymal transition (EMT), tumor cell proliferation, tumor microenvironment, and cellular metabolic status, which remains a significant challenge in clinical oncology, accounting for a majority of cancer-related deaths. TEAD4, a key mediator of the Hippo signaling pathway, has been implicated in regulating
-
Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-01 Marta Ostrowska-Lesko, Alicja Rajtak, Gema Moreno-Bueno, Marcin Bobinski
The tumor microenvironment (TME) components play a crucial role in cancer cells' resistance to chemotherapeutic agents. This phenomenon is exceptionally fundamental in patients with ovarian cancer (OvCa), whose outcome depends mainly on their response to chemotherapy. Until now, most reports have focused on the role of cellular components of the TME, while less attention has been paid to the stroma
-
A metabolic perspective on nitric oxide function in melanoma Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-05 John Jimenez, Parul Dubey, Bethany Carter, John M. Koomen, Joseph Markowitz
Nitric oxide (NO) generated from nitric oxide synthase (NOS) exerts a dichotomous effect in melanoma, suppressing or promoting tumor progression. This dichotomy is thought to depend on the intracellular NO concentration and the cell type in which it is generated. Due to its central role in the metabolism of multiple critical constituents involved in signaling and stress, it is crucial to explore NO's
-
Dual role of Snail1 as transcriptional repressor and activator Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-02 Antonio García de Herreros
Snail1 transcriptional factor plays a key role in the control of epithelial to mesenchymal transition, a process that remodels tumor cells increasing their invasion and chemo-resistance as well as reprograms their metabolism and provides stemness properties. During this transition, Snail1 acts as a transcriptional repressor and, as growing evidences have demonstrated, also as a direct activator of
-
Role of F-box proteins in human upper gastrointestinal tumors Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-12-02 Che Zhang, Guangzhao Pan, Jiang-Jiang Qin
Protein ubiquitination and degradation is an essential physiological process in almost all organisms. As the key participants in this process, the E3 ubiquitin ligases have been widely studied and recognized. F-box proteins, a crucial component of E3 ubiquitin ligases that regulates diverse biological functions, including cell differentiation, proliferation, migration, and apoptosis by facilitating
-
B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-28 Huan Zhang, Mengxin Zhu, Anjing Zhao, Tongguo Shi, Qinhua Xi
Colorectal cancer (CRC) is a common malignant tumor of the gastrointestinal tract and one of the most common causes of cancer-related deaths worldwide. Immune checkpoint inhibitors have become a milestone in many cancer treatments with significant curative effects. However, its therapeutic effect on colorectal cancer is still limited. B7-H3 is a novel immune checkpoint molecule of the B7/CD28 family
-
Current advances in comprehensive omics data mining for oncology and cancer research Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-25 Euna Jeong, Sukjoon Yoon
The availability of a large amount of multiomics data enables data-driven discovery studies on cancers. High-throughput data on mutations, gene/protein expression, immune scores (tumor-infiltrating cells), drug screening, and RNAi (shRNAs and CRISPRs) screening are major integrated components of patient samples and cell line datasets. Improvements in data access and user interfaces make it easy for
-
Fingerprint of the oxido-reductase ERO1: A protein disulfide bond producer and supporter of cancer Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-24 Ester Zito, Luca Guarrera, Yvonne M.W. Janssen-Heininger
Endoplasmic reticulum oxidoreductin 1 (ERO1) alpha (ERO1A) is an endoplasmic reticulum (ER)-localized protein disulfide oxidoreductase, involved in the disulfide bond formation of proteins. ERO1's activity in oxidative protein folding is redundant in higher eukaryotes and its loss is well compensated. Although it is dispensable in non-cancer cells, high ERO1 levels are seen with different cancers and
-
Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-29 Shenglong Li, Yue Kang, Yu Zeng
Despite standard hormonal therapy that targets the androgen receptor (AR) attenuates prostate cancer (PCa) effectively in the initial stage, the tumor ultimately converts to castration-resistant prostate cancer (CRPC), and the acquired resistance is still a great challenge for the management of advanced prostate cancer patients. The tumor microenvironment (TME) consists of multiple cellular and noncellular
-
Dysregulation of delta Np63 alpha in squamous cell carcinoma and its therapeutic targeting Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-29 Anurima Samanta, Priyanka Saha, Olivia Johnson, Anupam Bishayee, Dona Sinha
The gene p63 has two isoforms -a full length transactivated isoform (TA) p63 and an amino-terminally truncated isoform, ∆Np63. DeltaNp63 alpha (∆Np63α) is the predominant splice variant of the isoform, ∆Np63 and is expressed in the basal layer of stratified epithelia. ∆Np63α that is normally essential for the epithelial lineage maintenance may be dysregulated in squamous cell carcinomas (SCCs). The
-
Tumor microenvironment crosstalk between tumors and the nervous system in pancreatic cancer: Molecular mechanisms and clinical perspectives Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-28 Wenchao Xu, Jianzhou Liu, Jianlu Zhang, Jun Lu, Junchao Guo
Pancreatic ductal adenocarcinoma (PDAC) exhibits the highest incidence of perineural invasion among all solid tumors. The intricate interplay between tumors and the nervous system plays an important role in PDAC tumorigenesis, progression, recurrence, and metastasis. Various clinical symptoms of PDAC, including anorexia and cancer pain, have been linked to aberrant neural activity, while the presence
-
Untangling the web of intratumor microbiota in lung cancer Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-20 Weici Liu, Jingtong Xu, Zheshun Pi, Yundi Chen, Guanyu Jiang, Yuan Wan, Wenjun Mao
-
ASPORIN: A root of the matter in tumors and their host environment Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-24 Shobhit P. Lall, Zahraa W. Alsafwani, Surinder K. Batra, Parthasarathy Seshacharyulu
Asporin (ASPN) has been identified as one of the members of the class I small leucine-rich proteoglycans (SLRPs) family in the extracellular matrix (ECM). It is involved in classic ensigns of cancers such as self-dependent growth, resistance to growth inhibitors, restricting apoptosis, cancer metastasis, and bone-related disorders. ASPN is different from other members of SLRPs, such as decorin (DCN)
-
Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-20 Pankaj Garg, Atish Mohanty, Sravani Ramisetty, Prakash Kulkarni, David Horne, Evan Pisick, Ravi Salgia, Sharad S. Singhal
Gynecological cancers including breast, cervical, ovarian, uterine, and vaginal, pose the greatest threat to world health, with early identification being crucial to patient outcomes and survival rates. The application of machine learning (ML) and artificial intelligence (AI) approaches to the study of gynecological cancer has shown potential to revolutionize cancer detection and diagnosis. The current
-
Tunneling nanotubes: The intercellular conduits contributing to cancer pathogenesis and its therapy Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-20 Pooja Kamal Melwani, Badri Narain Pandey
-
Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-20 Sirui Zhang, Xiaozhen Zhang, Hanshen Yang, Tingbo Liang, Xueli Bai
Glucose metabolism is essential for the activation, differentiation and function of T cells and proper glucose metabolism is required to maintain effective T cell immunity. Dysregulation of glucose metabolism is a hallmark of cancer, and the tumour microenvironment (TME2) can create metabolic barriers in T cells that inhibit their anti-tumour immune function. Targeting glucose metabolism is a promising
-
Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents? Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-18 A. Gielecińska, M. Kciuk, E.-B. Yahya, T. Ainane, S. Mujwar, R. Kontek
For decades, common chemotherapeutic drugs have been established to trigger apoptosis, the preferred immunologically “silent” form of cell death. The primary objective of this review was to show that various FDA-approved chemotherapeutic drugs, including cisplatin, cyclosporine, doxorubicin, etoposide, 5-fluorouracil, gemcitabine, paclitaxel, or vinblastine can trigger necroptosis and pyroptosis. We
-
Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-16 Qian Liu, Ann M. Bode, Xue Chen, Xiangjian Luo
The high prevalence of metabolic reprogramming in nasopharyngeal carcinoma (NPC) offers an abundance of potential therapeutic targets. This review delves into the distinct mechanisms underlying metabolic reprogramming in NPC, including enhanced glycolysis, nucleotide synthesis, and lipid metabolism. All of these changes are modulated by Epstein-Barr virus (EBV) infection, hypoxia, and tumor microenvironment
-
Finding the junction between claudins and endometrial carcinoma Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-10 Davide Capoferri, Eliana Bignotti, Antonella Ravaggi, Stefania Mitola, Chiara Romani
Endometrial carcinoma (EC) defines a heterogeneous group of neoplastic diseases originating from the transformation of endometrial cells that constitute the internal lining of the uterus. To date several molecular targets have been analysed to describe the natural course of the disease, claudins being among these. Claudins are the main components of tight junctions (TJs), and their main functions are
-
Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-10 Rajesh N. Gacche
Targeting angiogenesis has remained one of the important aspects in disease biology in general and cancer in particular. Currently (June 2023), over 593 clinical trials have been registered at ClinicalTrials.gov having inference of term ‘angiogenesis’. A panel of 14 anti-angiogenic drugs have been approved by FDA for the treatment of variety of cancers and other human ailments. Although the anti-angiogenic
-
RORγT agonists as immune modulators in anticancer therapy. Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-10 Joanna Pastwińska, Iwona Karwaciak, Kaja Karaś, Rafał A. Bachorz, Marcin Ratajewski
RORγT is a transcription factor that directs the development of Th17 lymphocytes and other IL-17-expressing cells (e.g., Tc17 and ILC3 cells). These cells are involved in the body's defense against pathogenic bacteria and fungi, but they also participate in maintaining the proinflammatory environment in some autoimmune diseases and play a role in the immune system's response to cancer. Similar to other
-
The role of dysregulated mRNA translation machinery in cancer pathogenesis and therapeutic value of ribosome-inactivating proteins Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-07 Wentao Jia, Jiaying Yuan, Shu Li, Binbin Cheng
Dysregulated protein synthesis is a hallmark of tumors. mRNA translation reprogramming contributes to tumorigenesis, which is fueled by abnormalities in ribosome formation, tRNA abundance and modification, and translation factors. Not only malignant cells but also stromal cells within tumor microenvironment can undergo transformation toward tumorigenic phenotypes during translational reprogramming
-
Protein induced by vitamin K absence or antagonist II: Experience to date and future directions Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-07 Libin Dong, Xun Qiu, Fengqiang Gao, Kai Wang, Xiao Xu
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with high mortality. The realization of precision medicine in HCC relies upon efficient biomarkers. Protein induced by vitamin K absence or antagonist II (PIVKA-II) is an immature prothrombin with insufficient coagulation activity, overexpressing in HCC cells. Previous evidence confirmed the role of PIVKA-II in screening
-
Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-10-31 Xiangdong Liu, Bo Luo, Xinhong Wu, Zijian Tang
Breast cancer is one of the most common malignant tumors in women worldwide, and thus, it is important to enhance its treatment efficacy [1]. Copper has emerged as a critical trace element that affects various intracellular signaling pathways, gene expression, and biological metabolic processes [2], thereby playing a crucial role in the pathogenesis of breast cancer. Recent studies have identified
-
Harnessing tumor immunogenomics: Tumor neoantigens in ovarian cancer and beyond Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-05 Mengrui Wu, Shengtao Zhou
Ovarian cancer is a major cause of death among gynecological cancers due to its highly aggressive nature. Immunotherapy has emerged as a promising avenue for ovarian cancer treatment, offering targeted approaches with reduced off-target effects. With the advent of next-generation sequencing, it has become possible to identify genomic alterations that can serve as potential targets for immunotherapy
-
Current understanding of brachyury in chordoma Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-10-30 Tianshun Ma, Jiwei Bai, Yazhuo Zhang
Chordomas are rare malignant tumors that pose significant challenges in terms of effective treatment options. Surgical resection remains the only established approach that has proven useful in the treatment of chordoma. However, recent evidence has shed light on the role of brachyury, also known as the T-gene and TBXT, as both a diagnostic marker and a potential therapeutic target in chordoma. Considering
-
Glioma and post-translational modifications: A complex relationship Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-10-31 Tomasz Pienkowski, Tomasz Kowalczyk, Dominik Cysewski, Adam Kretowski, Michal Ciborowski
Post-translational modifications (PTMs) are common covalent processes in biochemical pathways that alter protein function and activity. These modifications occur through proteolytic cleavage or attachment of modifying groups, such as phosphoryl, methyl, glycosyl, or acetyl groups, with one or more amino acid residues of a single protein. Some PTMs also present crosstalk abilities that affect both protein
-
Lyotropic liquid crystalline 2D and 3D mesophases: Advanced materials for multifunctional anticancer nanosystems Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-11-03 Henrique Araújo-Silva, Patricia V. Teixeira, Andreia C. Gomes, Marlene Lúcio, Carla M. Lopes
Cancer remains a leading cause of mortality. Despite significant breakthroughs in conventional therapies, treatment is still far from ideal due to high toxicity in normal tissues and therapeutic inefficiency caused by short drug lifetime in the body and resistance mechanisms. Current research moves towards the development of multifunctional nanosystems for delivery of chemotherapeutic drugs, bioactives
-
Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatments Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-10-31 Sanjeev Raghuwanshi, Andrei L. Gartel
Forkhead box (FOX) protein M1 (FOXM1) is a critical proliferation-associated transcription factor (TF) that is aberrantly overexpressed in the majority of human cancers and has also been implicated in poor prognosis. A comprehensive understanding of various aspects of this molecule has revealed its role in, cell proliferation, cell migration, invasion, angiogenesis and metastasis. The FOXM1 as a TF
-
Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy Biochim Biophys Acta Rev Cancer (IF 11.2) Pub Date : 2023-10-31 Yuxi Luo, Zhimin Zeng, Yunwei Liu, Anwen Liu
In recent years, immune checkpoint inhibitors (ICIs) have become a widely used treatment for non-small cell lung cancer (NSCLC), and the combination with traditional radiotherapy (RT) has shown significant potential in prolonging patient survival. However, both thoracic RT and ICIs can lead to cardiac toxicity, including radiation-induced heart damage (RIHD) and immunotherapy-related heart damage (IRHD)